Two CVM Researchers Among Recipients of First C3O Cancer Grants

Improved cancer chemotherapy and sarcomas treatment are among the research projects from North Carolina State University College of Veterinary Medicine faculty awarded inaugural C3O grants from the Consortium for Canine Comparative Oncology.

Steven Suter, an associate professor of Medical Oncology and medical director of the Canine Bone Marrow Transplant Unit, and Matthew Breen, the Oscar J. Fletcher Distinguished Professor of Comparative Oncology Genetics, were the CVM faculty recipients of the grants. Dr. Suter and Dr. Breen will collaborate with Duke Cancer Institute researchers on their projects.

A joint funding project from CVM and the Duke Cancer Institute, the C3O grants support research that will translate laboratory discoveries into therapeutic applications.

The following four projects received funding:

  • Dr. Suter and Dr. Ashutosh Chilkoti: “A Phase 1 Clinical Trial of CP-DOX in Dogs: A Novel Nanoparticle Formation of an Old Drug,” for treating dogs with high-grade B-cell lymphoma.
  • Dr. Breen and Dr. William Eward: “Development of a Personalized Medicine Pipeline for Treatment of Sarcomas,” to identify options for personalized sarcomas treatments in dogs and humans.
  • Dr. Breen and Dr. Eward: “A Cross Species Genomic Analysis of Osteosarcoma: Implications for Novel Therapeutic Approaches,” identifying molecular mechanisms of sarcomagenesis and determining therapeutic uses of drugs against mutation.
  • Dr. Breen and Dr. Brant Inman: “Identification of Carcinogen-Induced Mutational Signatures in Human and Canine Bladder Cancer,” designed to characterize a genetic signature of a carcinogen in cells and its appearance in tumors.

For more information on the C3O grants, go to www.c3oncology.org/funding.